Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1187

1.

Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

Carlson RW, Hudis CA, Pritchard KI; National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology; American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors; St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

J Natl Compr Canc Netw. 2006 Nov;4(10):971-9. Review.

PMID:
17112447
[PubMed - indexed for MEDLINE]
2.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID:
17610808
[PubMed - indexed for MEDLINE]
Free Article
3.

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID:
17919537
[PubMed - indexed for MEDLINE]
4.
5.

Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

Berry J.

Clin Ther. 2005 Nov;27(11):1671-84. Review.

PMID:
16368441
[PubMed - indexed for MEDLINE]
6.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ; American Society of Clinical Oncology.

J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12. Review.

PMID:
20625130
[PubMed - indexed for MEDLINE]
7.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
[PubMed - indexed for MEDLINE]
8.

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.

Conte P, Frassoldati A.

Breast J. 2007 Jan-Feb;13(1):28-35. Review.

PMID:
17214790
[PubMed - indexed for MEDLINE]
9.

Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.

Mouridsen HT.

Curr Med Res Opin. 2006 Aug;22(8):1609-21. Review.

PMID:
16870085
[PubMed - indexed for MEDLINE]
10.

Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?

Chung CT, Carlson RW.

Clin Breast Cancer. 2004 Sep;5 Suppl 1:S18-23. Review.

PMID:
15347435
[PubMed - indexed for MEDLINE]
11.

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.

van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI.

Cancer Treat Rev. 2010 Feb;36(1):54-62. doi: 10.1016/j.ctrv.2009.10.003. Epub 2009 Nov 26. Review.

PMID:
19944537
[PubMed - indexed for MEDLINE]
12.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
[PubMed - indexed for MEDLINE]
13.

Emerging role of aromatase inhibitors in the adjuvant setting.

Goss PE.

Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review.

PMID:
12902874
[PubMed - indexed for MEDLINE]
14.

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.

Buzdar AU.

Oncologist. 2003;8(4):335-41. Review.

PMID:
12897330
[PubMed - indexed for MEDLINE]
Free Article
15.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
[PubMed - indexed for MEDLINE]
16.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
[PubMed - indexed for MEDLINE]
17.

Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.

Ingle JN.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):900s-5s. Review.

PMID:
15701884
[PubMed - indexed for MEDLINE]
Free Article
18.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
[PubMed - indexed for MEDLINE]
19.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
[PubMed - indexed for MEDLINE]
20.

The role of aromatase inhibitors in early breast cancer.

Chung CT, Carlson RW.

Curr Treat Options Oncol. 2003 Apr;4(2):133-40. Review.

PMID:
12594939
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk